pain therapy market

chronic pain

An illustration of a brain

The pain therapy market » Chronic pain

What is neuropatic pain?

Pain is a negative feeling associated with damage to the body’s tissues and is crucial to survival. Sometimes damage to the tissues from trauma or some diseases, for example, viral infection, shingles and diabetes, results in neuropathic pain that does not resolve, and the pain becomes chronic. This has no survival value and, indeed, results in a real reduction in sufferers’ quality of life.

Focus on allodynia

PharmNovo initially focuses on neuropathic pain with allodynia. Allodynia is a distressing part of neuropathic pain states. It is pain on the skin from something that shouldn’t be painful. This makes simple day-to-day activities, such as getting dressed, very unpleasant, and this has a negative impact on sufferers’ quality of life.

Allodynia is common in neuropathic pain states such as shingles, diabetic neuropathy, physical injury to nerves and migraine. Existing treatments are largely ineffective, but the drug candidate PN6047 from PharmNovo, blocks allodynia in animal models, and its potential in the human condition is clear.

The drug candidate is being developed for neuropathic pain in general, but by focusing  the study on peripheral nerve pain with mechanical allodynia, a semi-quantitative way of measuring effect can be used, which increases the likelihood of demonstrating efficacy.

NEUROPATHIC PAIN POINTS

  • Neuropathic pain, occurs when a health condition affects the nerves that carry sensations to your brain.
  • Neuropathic pain is characterized by excessive sensitivity to stimuli, including allodyniaa condition in which pain is caused by a stimulus that does not usually elicit pain and hyperalgesia in which pain is exaggerated.
  • Neuropathic pain is caused by damage or disease affecting the sensory system. About 30% of all neuropathic pain happens because of diabetes.
  • Neuropathic pain is usually chronic; the body just sends pain signals to your brain unprompted. Neuropathic pain tends to get worse over time.
  • Most of the available treatments for neuropathic pain have only moderate efficacy and produce side effects that limit their use; therefore, there is a great need for new therapeutic approaches.
An illustration of a man having arm pain with arrows pointing to the brain

Latest news

View all
October 25, 2024

PharmNovo live at neurology theme event at RedEye

Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.

Read more
October 10, 2024

PharmNovo at the LSX Nordic Congress

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:

Read more
July 17, 2024

17.5 MEUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

Read more
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more